Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 Outcomes – A Retrospective Cohort Study
17 Pages Posted: 24 Jan 2022
More...Abstract
Background: REGEN-COV has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within 5 days of their diagnosis. We aim to determine the real-world effectiveness of REGEN-COV treatment against COVID-19-related hospitalization, severe illness and death.
Methods: A cohort study was performed using the data repositories of Israel’s largest healthcare organization. Patients diagnosed with COVID-19 between September 19, 2021 and December 8, 2021 who were treated with REGEN-COV were matched to patients diagnosed with COVID-19 between July 1, 2021 and December 8, 2021 who were not treated with REGEN-COV. Patients were followed until the occurrence of the outcome (i.e. severe COVID-19 illness, hospitalization, and death due to COVID-19) or until 28-days from the index date. Analysis was performed using Cox regression, with estimated treatment effectiveness defined as one minus the hazard ratio.
Findings: 289 patients treated with REGEN-COV were matched with 1,294 untreated patients. The estimated effectiveness of REGEN-COV in the first 28- days after treatment was 55.2% (95% CI: 21.5-74.5%) in preventing COVID-19-related hospitalization, 59.4% (95% CI: 20.2-79.4%) in preventing severe COVID-19 illness, and 93.8% (95% CI: 54.4-99.2%) in preventing COVID-19-related death. A secondary analysis indicated that REGEN-COV was more effective in preventing COVID-19-related hospitalization among individuals younger than 60 compared to individuals aged 60 years or older.
Interpretation: REGEN-COV was effective in reducing the risk of deterioration in high-risk COVID-19 patients. With many individuals remaining unvaccinated, and breakthrough infections occurring among the vaccinated, effective treatment for COVID-19 remains vital.
Funding Information: None.
Declaration of Interests: The authors has no conflict of interest to declare.
Ethics Approval Statement: This study was approved by the CHS Institutional Review Board.
Keywords: COVID-19 infection, SARS-CoV-2, REGEN-COV treatment, COVID-19 treatment, observational studies, treatment effectiveness, two SARS-CoV-2 antibodies (Casirivimab and Imdevimab)
Suggested Citation: Suggested Citation